Enterobacteriaceae Infections clinical trials
The registry lists 59 studies for Enterobacteriaceae Infections across more than 10 countries. 14 are recruiting or about to start. 51 of them are mainly about Enterobacteriaceae Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-29. Counting its 4 narrower conditions too, such as Escherichia coli Infections: 296 studies, 54 open.
Get an email when these change. Save the Enterobacteriaceae Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Rambam Health Care Campus (4) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (3) · Fondation Hôpital Saint-Joseph (2) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (2) · University Hospital, Geneva (2) · Maimónides Biomedical Research Institute of Córdoba (2) · Assistance Publique - Hôpitaux de Paris (2) · PATH (2)
What is being tested here
Drugs under test in Enterobacteriaceae Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5
- Dec 2026Study of Probiotic Adjunctive Therapy for Decolonization of Carbapenem-Resistant Enterobacterales · Second Affiliated Hospital, School of Medicine, Zhejiang University
- Dec 2026Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children · Children's Hospital of Fudan University
- Jan 2027PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN) · Rambam Health Care Campus
- Apr 2027Predictive Value of a Rectal Swab With Detection of Enterobacteria (ESBL-E), Carbapenemases, and High-level Cephalosporinase (HLC) on the Risk of Infections With C3G-resistant Enterobacteria · University Hospital, Strasbourg, France
- Oct 2027Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France · Centre Hospitalier Universitaire de Nīmes
Who these studies take
Of the 9 Enterobacteriaceae Infections studies recruiting now, 4 (44%) set no upper age limit and 2 (22%) stop at 75 or younger. 2 (22%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (22%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (11%) | 1 (11%) |
| 18 | 8 (89%) | 8 (89%) |
| 30 | 7 (78%) | 7 (78%) |
| 40 | 7 (78%) | 7 (78%) |
| 50 | 7 (78%) | 7 (78%) |
| 65 | 7 (78%) | 7 (78%) |
| 75 | 7 (78%) | 7 (78%) |
| 85 | 7 (78%) | 7 (78%) |
Across all 59 studies, recruiting or not: 10% stop at 75 or younger and 10% at 65; 25% take children; 0% are for women only and 2% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- Aztreonam-Avibactam in Immunocompromised HostsOct 22, 2026NCT07890480
Studies
Recruiting first, then most recently updated. Showing 50 of 59. Browse all 59 → or search them.
- Aztreonam-Avibactam in Immunocompromised HostsRecruitingNCT078904801 country
- Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern FranceNot yet recruitingNCT076765131 country
- Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant EnterobacteriaceaeNot yet recruitingNCT05981430Not applicable
- FMT for the Decolonization of Carbapenem-resistant EnterobacteriaceaeRecruitingNCT04759001Phase 1/21 country
- Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in ChildrenRecruitingNCT045356611 country
- Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Control Bundle in a Tertiary HospitalNot yet recruitingNCT07397416Not applicable
- Predictive Value of a Rectal Swab With Detection of Enterobacteria (ESBL-E), Carbapenemases, and High-level Cephalosporinase (HLC) on the Risk of Infections With C3G-resistant EnterobacteriaRecruitingNCT073459231 country
- Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant EnterobacteralesNot yet recruitingNCT071605691 country
- PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)RecruitingNCT03671967Phase 42 countries
- Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated AnimalsRecruitingNCT05871476Not applicable1 country
- Fecal Transplantation to Eradicate Colonizing Emergent SuperbugsRecruitingNCT05035342Phase 31 country
- FMT to Eradicate Intestinal Colonization by Carbapenem-resistant EnterobacteriaceaeRecruitingNCT05791396Phase 1/21 country
- Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill PatientsRecruitingNCT062585511 country
- Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK ModelNot yet recruitingNCT06210542
- Community-associated Highly-Resistant EnterobacteralesCompletedNCT039249341 country
- PMT for MDRO DecolonizationCompletedNCT05632315Phase 21 country
- Study of Probiotic Adjunctive Therapy for Decolonization of Carbapenem-Resistant EnterobacteralesActive, not recruitingNCT07707869Not applicable1 country
- Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.CompletedNCT04276480Not applicable1 country
- Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased PatientsCompletedNCT056118921 country
- Nosocomial Outbreak of BHRe in an Intensive Care Unit During SARS-CoV-2 PandemicCompletedNCT050554791 country
- ANTIBIOTIC-RESISTANT ENTEROBACTERALES BLOODSTREAM INFECTIONS AND RISK FACTORS IN PATIENTS ADMITTED TO THE INTENSIVE CARE UNITCompletedNCT071729321 country
- PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream InfectionsWithdrawnNCT05355350Phase 41 country
- The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant OrganismsCompletedNCT045830981 country
- A Novel Approach to Antimicrobial Resistance: Machine Learning Predictions for Carbapenem-Resistant Klebsiella in ICUsCompletedNCT059850571 country
- Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing EnterobacteriaceaeSuspendedNCT03891433Phase 41 country
- Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella PneumoniaeTerminatedNCT04760665Phase 21 country
- Drug Resistance Mechanism of Enterobacteriaceae and Its StrategiesStatus unknownNCT05850871Not applicable1 country
- Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant BacteriaStatus unknownNCT055164331 country
- Fecal Microbiota Transplantation for Carbapenem-resistant EnterobacteriaceaeCompletedNCT04146337Phase 2/31 country
- Fecal Microbiota Transplantation for Carbapenem Resistant EnterobacteriaceaeCompletedNCT04790565Phase 2/31 country
- Neonatal Acquisition of ESBL-PE in a Low-income Country - NeoLICStatus unknownNCT048362081 country
- Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From BloodCompletedNCT024820511 country
- Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care FacilitiesCompletedNCT034770841 country
- Cost-effectiveness of Controlling CPEStatus unknownNCT05272410
- Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant EnterobacteriaCompletedNCT041672281 country
- Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant BacteriaCompletedNCT03338738Not applicable1 country
- Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum EnterobacteriaceaeStatus unknownNCT049038861 country
- Oral Capsule Faecal Microbiota Transplantation for CPE DecolonizationStatus unknownNCT04746222Phase 2/3
- Infections and Colonization With the Third Group of Enterobacteriaceae in the Intensive Care UnitCompletedNCT045280431 country
- Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by EnterobacteriaceaeCompletedNCT02795949Phase 31 country
- Shigella WRSS1 Vaccine Trial in BangladeshCompletedNCT02934178Phase 11 country
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy ParticipantsCompletedNCT03491748Phase 11 country
- Factors Influencing the Fecal Relative Abundance of ESBL-producing Enterobacteriaceae in Intensive Care (BLSE-REA).Status unknownNCT04190316Not applicable
- Pilot Study Using Oral Capsule FMT to Decolonize GI CREWithdrawnNCT03527056Early Phase 1
- Prevention and Decolonization of Multidrug-resistant Bacteria With ProbioticsStatus unknownNCT03967301Not applicable
- Prevalence of ESBL and CPE in French Nursing HomesCompletedNCT034012421 country
- Safety Study of Live Attenuated Oral Shigella (WRSS1) Vaccine in Bangladeshi Adults and ChildrenCompletedNCT01813071Not applicable1 country
- Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia ColiCompletedNCT005732351 country
- Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing OrganismsCompletedNCT005735211 country
- The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian ToddlersStatus unknownNCT03411590Not applicable